Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Toripalimab with AG and SBRT in Pancreatic Cancer
NCT06080854Phase 2Not yet recruiting
- Sponsor
- Nanjing Drum-Tower Hospital
- Start
- Nov 2023
- Primary completion
- Jun 2025
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of toripalimab in pancreatic cancer (PC), sponsored by Nanjing Drum-Tower Hospital. Primary endpoints: Objective Response Rate at 2 years and R0 Resection Rate at 2 years. Planned start Nov 2023; status: not yet recruiting.
02
Drugs
toripalimab
03
Conditions
pancreatic cancer (PC)
Beyond the preview
Go deeper on NCT06080854.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06080854.